Efficacy of Intravenous Elosulfase Alfa for Mucopolysaccharidosis Type IVA: A Systematic Review and Meta-Analysis
Mucopolysaccharidosis type IVA (MPS IVA or Morquio A), a lysosomal storage disease with an autosomal recessive inherited pattern, is induced by <i>GALNS</i> gene mutations causing deficiency in N-acetylgalactosamine-6-sulfatase activity (GALNS; EC 3.1.6.4). Currently, intravenous (IV) en...
Main Authors: | Chung-Lin Lee, Chih-Kuang Chuang, Yu-Min Syu, Huei-Ching Chiu, Yuan-Rong Tu, Yun-Ting Lo, Ya-Hui Chang, Hsiang-Yu Lin, Shuan-Pei Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-08-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/12/8/1338 |
Similar Items
-
Role of elosulfase alfa in mucopolysaccharidosis IVA
by: Regier DS, et al.
Published: (2016-06-01) -
Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement
by: Bob Stevens, et al.
Published: (2021-09-01) -
Clinical characteristics and effects of enzyme replacement therapy with elosulfase alfa in Korean patients with mucopolysaccharidosis type IVA
by: Seung Hoon Lee, et al.
Published: (2022-06-01) -
Safety and Efficacy of Elosulfase Alfa in Australian Patients with Morquio a Syndrome: A Phase 3b Study
by: Kaustuv Bhattacharya, et al.
Published: (2020-05-01) -
Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience
by: Pilar Quijada-Fraile, et al.
Published: (2021-11-01)